drugset / Trial / NCT01349881
S0820, Adenoma and Second Primary Prevention Trial
Phase 3
Active not recruiting
354 enrolled
SWOG Cancer Research Network
Cancer Prevention Pharmaceuticals, Inc. · collabNational Cancer Institute (NCI) · collab
RandomizedFactorialTriple-blindPrevention
Summary
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Timeline
- Start
- 2013-08-23
- Primary completion
- 2027-09-15
- Completion
- 2032-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eflornithine | Small molecule | 500 mg | Oral |
| Subject | Sulindac | Small molecule | 150 mg | Oral |